Three myeloma experts yesterday presented additional clinical trial data on the possible link between Revlimid and secondary cancer in multiple myeloma patients.  All three experts concluded that Revlimid’s benefit as a myeloma treatment outweighs its risks.

The presentations were made at a session of the American Society of Clinical Oncology (ASCO) annual meeting in Chicago.

In a summary talk reviewing the three presentations, Dr. Ola Landgren from the U.S. National Cancer Institute noted that the risk of developing a secondary cancer following Revlimid (lenalidomide) therapy was significantly lower than a myeloma …

Yesterday was the third day of the American Society of Clinical Oncology (ASCO) 2011 annual meeting in Chicago, and it was especially packed with pre­sen­ta­tions re­lated to mul­ti­ple myeloma.

There was a morn­ing session where a total of eight re­search abstracts were pre­sented and discussed.  Then, late in the afternoon, there was an education session focused on mul­ti­ple myeloma, with sev­er­al dif­fer­en­t pre­sen­ta­tions.

The pre­sen­ta­tions during the morn­ing session were on three dif­fer­en­t topics: Revlimid (lena­lido­mide) and its po­ten­tial link to sec­ond­ary cancer; myeloma bone dis­ease; and new drugs being devel­oped as po­ten­tial …

This year’s American Society of Clinical Oncology (ASCO) annual meeting, which began on Friday and goes through Tuesday, is being held in Chicago.

On the first day of the meeting, there was only one talk related to multiple myeloma.  During an afternoon education session, in which current practice and recent research results are reviewed, Dr. Raphael Fonseca from the Mayo Clinic in Scottsdale, Arizona, spoke about high-risk multiple myeloma.

The second day of the meeting included a morning and an afternoon session in which myeloma researchers presented their findings in the form …

The International Myeloma Working Group, a group of leading myeloma specialists, recently drafted guidelines for the prevention of blood clots in the veins in multiple myeloma patients. The group recommended the use of heparin or warfarin for patients with a high risk for developing blood clots and aspirin for standard-risk patients.

Dr. Antonio Palumbo of the University of Torino in Italy presented the draft guidelines at the International Myeloma Workshop (IMW) on May 6 in Paris. In email correspondence with The Myeloma Beacon, Dr. Palumbo said that a comprehensive set of guidelines …

The 47th annual meeting of the American Society of Clinical Oncology (ASCO) will take place Friday, June 3, through Tuesday, June 7, in Chicago.

More than 30,000 clin­i­cal spe­cialists from all over the world are ex­pected to attend the five-day meeting to discuss the cur­rent re­search in cancer treat­ment and care. This year’s meeting will primarily focus on the theme of “Patients, Pathways, Progress.”

The meeting will in­clude many pre­sen­ta­tions and seminars focused spe­cif­i­cally on mul­ti­ple myeloma. The ASCO website cur­rently lists over 40 myeloma-based abstracts.

The Myeloma Beacon will be …

A group of leading myeloma specialists, known as the International Myeloma Working Group, recently collaborated to develop guidelines for the proper management of anemia with erythropoietin therapy in multiple myeloma patients. The group advised erythropoietin therapy for anemic myeloma patients receiving chemotherapy in order to improve quality of life and to reduce the need for red blood cell transfusions. They further recommended the addition of iron to improve the efficiency of erythropoietin therapy.

Dr. Heinz Ludwig of the Wilhelminen Hospital in Vienna, Austria, presented these guidelines at the International Myeloma Workshop (IMW) …

Myeloma researchers and physicians gathered at the 2011 International Myeloma Workshop (IMW) earlier this month to discuss the current under­standing of the biology and treatment of multiple myeloma.

Highlights from each day of the workshop were covered in the Beacon’s daily updates from the meeting.

Now that the IMW has ended, however, and there has been some time to digest all that happened, it seems like a good time to ask: What were the key themes and learnings from the conference?

To answer this question, The Beacon went back and reviewed its coverage of the IMW, and …